Skip to content

Study of Dermatonics Heel Balm compared to Moisturex cream for the Reduction/Removal of Hard Callused Plantar skin

An open label, single center, Investigator initiated, pilot study to determine the efficacy and safety of topical use of Dermatonics Heel Balm as compared to Moisturex cream for the Reduction/Removal of Hard Callused Plantar Skin.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045825
Enrollment
10
Registered
2022-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L84- Corns and callosities

Interventions

Intervention1: Dermatonics Heel Balm: Dose- 1cm of Dermatonics Heel Balm is to be applied on affected area. Frequency- Twice a day(12 hours apart) Total Duration- 3 days in total and is to applied on

Sponsors

Dr Anjeeta Dhawan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diabetic patients with dry and callused skin (Grading ââ?¬â??1-5). 2. Subjects who are healthy with no significant concurrent illnesses or skin disease. 3. Subjects with visibly dry and rough skin on their heels. 4. Participants who will be able to provide written informed consent prior to the performance of any study specific procedures. 5. Female participants of child-bearing potential with negative serum pregnancy test at screening and negative urine pregnancy test at the time of screening. 6. Participants who are willing and able to comply with all study assessments and adhere to the protocol schedule.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating females or females of reproductive age not using a reliable form of contraception. 2. Subjects who take any medication likely to interfere with the study. 3. Subjects with a history of significant skin disease (e.g. eczema, psoriasis) 4. Subjects with an allergy likely to interfere with the study. 5. Subjects who are unwilling or unable to give written consent. 6. Patients involved in clinical trials and taken Investigational drugs within 30 days of enrolment.

Design outcomes

Primary

MeasureTime frame
Analysis of reduction in the callus on the basis of assessment scale with detailed photographs having following Grades- ➢ Grade 0: smooth, fine lines, and no dryness ➢ Grade 1: dry lines, slight scaling, and skin thickening ➢ Grade 2: small fissures, moderate scaling, and skin thickening ➢ Grade 3: deep fissures, obvious scaling, and skin thickening ➢ Grade 4: small gaps on fissures, severe scaling, and skin thickening. ➢ Grade 5: Big gaps and Opening on Fissures, bleeding, extreme scaling and skin thickening. Improvement in Hydration based on ââ?¬Å?The Young Townson Foot skin hydration scaleââ?¬?. Graded as: Level 1: Well hydrated heels, with little or no signs of drying, Level 2: Drying skin but no callus, Level 3: Drying skin combined with callus, Level 4: Callused skin with open slits.Timepoint: day 0, 1st and 3rd

Secondary

MeasureTime frame
Improvement in General skin condition, skin colour and cracks. Any discoloration or hyperpigmentation and change in cracks on Day 1 and Day3, when compared to day 0. ââ?¬Â¢ Perception of pain associated with crack and ulceration using a tenpoint scale in volunteers with grade 2-5 callus (Grading mentioned in Primary outcome first point). Pain Reduction from day 0 to day 3 using the ââ?¬Å?Wong-Baker Facesââ??¢ Pain Rating Scaleââ?¬? (Annexure II). ââ?¬Â¢ Any adverse event during the study. ââ?¬Â¢ To evaluate experience of subjects by assessing questionnaire - SPQs (self-perception questionnaires) to be completed by each subject on Day 1 and Day 3. ) Safety Endpoints ââ?¬Â¢ Adverse events (AEs) monitoring during the study period. ââ?¬Â¢ Skin irritation or tolerability assessment. (Annexure IV) ââ?¬Â¢ Physical examination & vital signsTimepoint: Day 1 and Day 3

Countries

India

Contacts

Public ContactArun Semwal

CliniExperts Services Pvt. Ltd.

arun.chandra@cliniexpertsresearch.com9555564408

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026